Company intelligence / Profile preview
Aquestive Therapeutics
- Ownership
- Public · AQST
- Employees
- ~175
- Development stage
- Commercial
Overview
Aquestive has completed pivotal Phase III studies for Anaphylm™ (epinephrine sublingual film) showing comparable or faster absorption than leading autoinjectors. NDA submission to FDA expected Q1 2025; pediatric data in line with expectations. Five products are already commercialized through licensees, including Sympazan® oral film for Lennox-Gastaut Syndrome[3][7][10].
- Therapeutic areas
- DermatologyImmunologyNeurology
- Modalities
- Oral film drug delivery (PharmFilm® technology)Topical gel formulations
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $653.7M
- Total revenue
- $13.8M
- Enterprise value
- $614.2M
Beyond the preview
Go deeper on Aquestive Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aquestive Therapeutics.